Neovacs S.A EV / EBITDA
Was ist das EV / EBITDA von Neovacs S.A?
EV / EBITDA von Neovacs S.A. ist 3.93
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf EURONEXT im Vergleich zu Neovacs S.A
Was macht Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Unternehmen mit ev / ebitda ähnlich Neovacs S.A
- JNBY Design hat EV / EBITDA von 3.92
- ICO hat EV / EBITDA von 3.93
- Hydratec Industries NV hat EV / EBITDA von 3.93
- Independence Contract Drilling Inc hat EV / EBITDA von 3.93
- Steel City Securities hat EV / EBITDA von 3.93
- Rio Tinto Plc hat EV / EBITDA von 3.93
- Neovacs S.A hat EV / EBITDA von 3.93
- Supremex hat EV / EBITDA von 3.93
- Arkema SA hat EV / EBITDA von 3.93
- Dlsi hat EV / EBITDA von 3.93
- Albert David hat EV / EBITDA von 3.94
- Sino-Life hat EV / EBITDA von 3.94
- Signet Jewelers Ltd hat EV / EBITDA von 3.94